Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 4/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.39 |
| ▸ | TRHR | P34981 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.37 |
| ▸ | APLNR | P35414 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11308638 | 0.92 | TRHR (0.42) | MC4RTRHR | |
| SCHEMBL29630369 | 0.87 | TRHR (0.41) | TRHROPRM1OPRD1 | |
| SCHEMBL29590456 | 0.87 | TRHR (0.41) | TRHR | |
| SCHEMBL29630526 | 0.87 | TRHR (0.41) | TRHR | |
| SCHEMBL11203821 | 0.86 | TRHR (0.46) | TRHR | |
| SCHEMBL11308630 | 0.86 | ACE (0.45) | MC4RTRHR | |
| SCHEMBL30258236 | 0.86 | F2 (0.45) | MC4RF2APLNR | |
| SCHEMBL29630670 | 0.85 | TRHR (0.42) | TRHR | |
| SCHEMBL29555036 | 0.84 | ACE (0.41) | MC4RF2TRHRCAPN1APLNR | |
| SCHEMBL29591934 | 0.84 | GRB2 (0.43) | MC4RF2TRHRAPLNROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | MC4R 4867/4885BDKRB2 4190/4885F2 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.